• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by LENZ Therapeutics Inc.

    7/29/24 4:12:50 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LENZ alert in real time by email
    SC 13G 1 tm2420256d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Amendment No. __)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 19341

     

    LENZ Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    52635N103

    (CUSIP Number)

     

    July 17, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP NO. 52635N10313GPage 2 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Investments L.P.               66-0677421

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨ 
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    1,951,875

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    1,951,875

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,951,875

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.2%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

     

    CUSIP NO. 52635N10313GPage 3 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Investments LLC              72-1614961

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    1,951,875

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    1,951,875

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,951,875

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.2%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

     

    CUSIP NO. 52635N10313GPage 4 of 10

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ridgeback Capital Management LLC              42-1684320

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP** (a) ¨
    (b) ¨
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    -0-

    6.

    SHARED VOTING POWER

     

    1,951,875

    7.

    SOLE DISPOSITIVE POWER

     

    -0-

    8.

    SHARED DISPOSITIVE POWER

     

    1,951,875

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,951,875

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES**

     

    ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.2%

    12.

    TYPE OF REPORTING PERSON**

     

    OO

     

    ** SEE INSTRUCTIONS BEFORE FILLING OUT

     

     

    CUSIP NO. 52635N10313GPage 5 of 10

     

    Item 1(a). Name of Issuer.

     

    LENZ Therapeutics, Inc. (the “Company”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.

     

    The Company’s principal executive offices are located at 445 Marine View Ave., Ste. #320, Del Mar, California 92014.

     

    Items 2(a). Name of Person Filing.

     

    This statement is filed on behalf of the following persons with respect to shares of common stock of the Company acquired by them (the “Shares”):

     

    (i)Ridgeback Capital Investments L.P., Delaware limited partnership (“RCILP”), with respect to Shares beneficially owned by it;

     

    (ii)Ridgeback Capital Investments LLC, a Delaware limited liability company (“RCI”), with respect to Shares beneficially owned by it; and

     

    (iii)Ridgeback Capital Management LLC, a Delaware limited liability company (“RCM”), with respect to Shares beneficially owned by it.

     

    The foregoing persons are hereinafter referred to collectively as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence.

     

    The address of the principal business office of each of the Reporting Persons is 30 Star Island Drive, Miami, FL, 33139.

     

    Item 2(c).Citizenship.

     

    RCILP is a Delaware limited partnership. RCI is a Delaware limited liability company. RCM is a Delaware limited liability company.

     

    Item 2(d).Title of Class of Securities.

     

    Common stock, $0.00001 par value per share.

     

     

    CUSIP NO. 52635N10313GPage 6 of 10

     

    Item 2(e).CUSIP Number.

     

    52635N103

    Item 3.

     

    If this statement is filed pursuant to Rules 13d-1(b) or 13d- 2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act,
    (b) ¨  Bank as defined in Section 3(a)(6) of the Act,
    (c) ¨  Insurance Company as defined in Section 3(a)(19) of the Act,
    (d) ¨  Investment Company registered under Section 8 of the Investment Company Act of 1940,
    (e) ¨  Investment Adviser in accordance with Rule 13d-1 (b)(1)(ii)(E),
    (f) ¨  Employee Benefit Plan or Endowment Fund in accordance with 13d-1 (b)(1)(ii)(F),
    (g) ¨  Parent Holding Company or control person in accordance with Rule 13d-1 (b)(1)(ii)(G),
    (h) ¨  Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
    (i) ¨  Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
    (j) ¨  A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _______________.

     

    Item 4.Ownership.

     

    The percentages used herein are calculated based upon 27,113,405 shares outstanding, consisting of 25,534,458 shares outstanding as of May 3, 2024 as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 8, 2024, plus 1,578,947 issued to RCILP on July 17, 2024. As of the close of business on July 17, 2024, the Reporting Persons beneficially owned shares of the Company’s common stock in the amounts and percentages listed below:

     

    A. Ridgeback Capital Investments L.P.
    (a) Amount beneficially owned:  1,951,875

     

     

    CUSIP NO. 52635N10313GPage 7 of 10

     

    (b) Percent of class: 7.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  1,951,875
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  1,951,875
         
    B. Ridgeback Capital Investments LLC
    (a) Amount beneficially owned:  1,951,875
    (b) Percent of class: 7.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  1,951,875
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  1,951,875
       
    C. Ridgeback Capital Management LLC
    (a) Amount beneficially owned:  1,951,875
    (b) Percent of class: 7.2%
    (c) (i) Sole power to vote or direct the vote: -0-
      (ii) Shared power to vote or direct the vote:  1,951,875
      (iii) Sole power to dispose or direct the disposition:  -0-
      (iv) Shared power to dispose or direct the disposition:  1,951,875

     

    RCM and RCI do not own any Shares directly. RCI is the general partner of RCILP. Pursuant to an investment management agreement, RCM maintains investment and voting power with respect to the securities held or controlled by RCI. Wayne Holman, an individual, controls RCM. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, RCM and RCI may be deemed to own beneficially all of the Shares (constituting approximately 7.2% of the shares outstanding). Each of RCM and RCI disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein.

     

     

    CUSIP NO. 52635N10313GPage 8 of 10

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.   ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the Shares which represents more than five percent of the number of outstanding shares of the Shares.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    Each of the Reporting Persons hereby makes the following certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP NO. 52635N10313GPage 9 of 10

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATED: July 29, 2024

     

        Ridgeback Capital Investments L.P.
         
        By: Ridgeback Capital Investments LLC,
        Its General Partner
         
      By: /s/ Nicole Venezia
        Name: Nicole Venezia
        Title: General Counsel
         
        Ridgeback Capital Investments LLC
         
      By: /s/ Nicole Venezia
        Name: Nicole Venezia
        Title: General Counsel
         
        Ridgeback Capital Management LLC
         
      By: /s/ Nicole Venezia
        Name:   Nicole Venezia
        Title: General Counsel

     

     

    CUSIP NO. 52635N10313GPage 10 of 10

     

    EXHIBIT INDEX

     

    Exhibit Number   Exhibit Description
    99.1   Joint Filing Agreement

     

     

     

    Get the next $LENZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LENZ

    DatePrice TargetRatingAnalyst
    4/14/2025$38.00 → $51.00Overweight
    Piper Sandler
    3/18/2025$60.00Buy
    TD Cowen
    9/27/2024$37.00Outperform
    Raymond James
    8/12/2024$38.00Buy
    H.C. Wainwright
    4/15/2024Outperform
    William Blair
    4/15/2024$32.00Outperform
    Leerink Partners
    4/10/2024$34.00Buy
    Citigroup
    3/27/2024$28.00Overweight
    Piper Sandler
    More analyst ratings

    $LENZ
    Financials

    Live finance-specific insights

    See more
    • LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presby

      5/7/25 4:05:00 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

      SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 8251197. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Inve

      4/30/25 4:30:00 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

      New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth quarter of 2025 Cash, cash equivalents and marketable securities of $209.1 million as of December 31, 2024; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EST SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first a

      3/19/25 4:05:00 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chevallard Daniel R. bought $49,988 worth of shares (3,188 units at $15.68) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/15/24 4:13:06 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

      SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. Lotus is a leading global pharmaceutical company focused on commercializing novel pharmaceuticals to provide pa

      5/9/25 9:03:48 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presby

      5/7/25 4:05:00 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in a fireside chat and one-on-one meetings at the BofA Securities 2025 Health Care Conference taking place May 13- 15, 2025 in Las Vegas, NV. Details of the event are as follows:Date: Tuesday, May 13, 2025Location: Encore Hotel, Las Vegas, NevadaTime: 9:20am PDT / 12:20pm EDT A live audio webcast of the BofA Securities 2025 Health Care Conference present

      5/6/25 4:30:48 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on LENZ Therapeutics with a new price target

      Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously

      4/14/25 8:17:08 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on LENZ Therapeutics with a new price target

      TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00

      3/18/25 7:53:26 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on LENZ Therapeutics with a new price target

      Raymond James initiated coverage of LENZ Therapeutics with a rating of Outperform and set a new price target of $37.00

      9/27/24 7:38:17 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lucy Therapeutics Appoints Kim Drapkin as Board Chair

      Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st

      10/15/24 8:00:00 AM ET
      $ABOS
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

      Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader ("KOL") event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectiv

      6/10/24 8:00:00 AM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Olsson Shawn exercised 1,400 shares at a strike of $2.08, increasing direct ownership by 42% to 4,733 units (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      4/9/25 7:20:28 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, CEO and Secretary Schimmelpennink Evert B. exercised 4,200 shares at a strike of $1.04, increasing direct ownership by 9% to 49,200 units (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/7/25 6:10:43 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Olsson Shawn

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      1/13/25 5:26:58 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by LENZ Therapeutics Inc.

      SCHEDULE 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      5/9/25 4:19:30 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by LENZ Therapeutics Inc.

      10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/7/25 4:16:06 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • LENZ Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/7/25 4:09:09 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LENZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by LENZ Therapeutics Inc.

      SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      11/14/24 4:00:05 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by LENZ Therapeutics Inc.

      SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      11/8/24 5:08:56 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by LENZ Therapeutics Inc.

      SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

      7/29/24 4:12:50 PM ET
      $LENZ
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care